A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
Animals
Dipeptidyl Peptidase 4
/ genetics
Dipeptidyl-Peptidase IV Inhibitors
/ pharmacology
Fibrosis
Linagliptin
/ pharmacology
Male
Matrix Metalloproteinase 2
/ metabolism
Myocardial Infarction
/ drug therapy
Rats, Inbred F344
Rats, Wistar
Transforming Growth Factor beta1
/ metabolism
Ventricular Function, Left
/ drug effects
Dipeptidyl peptidase-4
Fibrosis
Left ventricular diastolic function
Macrophage
Myocardial infarction
Journal
Journal of pharmacological sciences
ISSN: 1347-8648
Titre abrégé: J Pharmacol Sci
Pays: Japan
ID NLM: 101167001
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
08
08
2018
revised:
06
12
2018
accepted:
11
12
2018
pubmed:
15
1
2019
medline:
18
4
2019
entrez:
15
1
2019
Statut:
ppublish
Résumé
Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as preconditioning effect for myocardial ischemia-reperfusion injury. Here, we investigated the anti-remodeling effects of linagliptin, a DPP-4 inhibitor, by use of DPP-4-deficient rats. After the induction of myocardial infarction (MI), Fischer 344 rats with inactivating mutation of DPP-4 were orally administrated with a DPP-4 inhibitor, linagliptin (5 mg kg
Identifiants
pubmed: 30638989
pii: S1347-8613(18)30226-3
doi: 10.1016/j.jphs.2018.12.004
pii:
doi:
Substances chimiques
Dipeptidyl-Peptidase IV Inhibitors
0
Tgfb1 protein, rat
0
Transforming Growth Factor beta1
0
Linagliptin
3X29ZEJ4R2
DPP4 protein, rat
EC 3.4.14.5
Dipeptidyl Peptidase 4
EC 3.4.14.5
Matrix Metalloproteinase 2
EC 3.4.24.24
Mmp2 protein, rat
EC 3.4.24.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112-119Informations de copyright
Copyright © 2018 The Authors. Production and hosting by Elsevier B.V. All rights reserved.